scholarly journals Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours

2017 ◽  
Vol 6 (8) ◽  
pp. 876-885 ◽  
Author(s):  
Logan Mills ◽  
Panagiotis Drymousis ◽  
Yogesh Vashist ◽  
Christoph Burdelski ◽  
Andreas Prachalias ◽  
...  
Keyword(s):  
Roc Analysis ◽  
Neuroendocrine Tumours ◽  
Predictive Variables ◽  
Low Malignant Potential ◽  
Long Term Follow Up ◽  
Pancreatic Neuroendocrine Tumours ◽  
Radiological Changes ◽  
Tumour Characteristics

Small non-functioning pancreatic NETs (pNETs) ≤2 cm can pose a management dilemma in terms of surveillance or resection. There is evidence to suggest that a surveillance approach can be considered since there are no significant radiological changes observed in lesions during long-term follow-up. However, other studies have suggested loco-regional spread can be present in ≤2 cm pNETs. The aim of this study was to characterise the prevalence of malignant features and identify any useful predictive variables in a surgically resected cohort of pNETs. 418 patients with pNETs were identified from 5 NET centres. Of these 227 were included for main analysis of tumour characteristics. Mean age of patients was 57 years, 47% were female. The median follow-up was 48.2 months. Malignant features were identified in 38% of ≤2 cm pNETs. ROC analysis showed that the current cut-off of 20 mm had a sensitivity of 84% for malignancy. The rate of malignant features is in keeping with other surgical series and challenges the belief that small pNETs have a low malignant potential. This study does not support a 20 mm size cut-off as being a solitary safe parameter to exclude malignancy in pNETs.

Prognostic factors that mandate long term follow up following surgery for appendix neuroendocrine tumours (aNETs)

2016 ◽  
Author(s):  
Edward Alabraba ◽  
Heman Joshi ◽  
Andrea Tufo ◽  
Hassan Malik ◽  
Melissa Banks ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Neuroendocrine Tumours ◽  
Long Term Follow Up

scholarly journals Comparison of robot-assisted retroperitoneal laparoscopic adrenalectomy versus retroperitoneal laparoscopic adrenalectomy for large pheochromocytoma: a single-centre retrospective study

BMC Surgery ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Sheng-Qiang Fu ◽  
Chang-Shui Zhuang ◽  
Xiao-Rong Yang ◽  
Wen-Jie Xie ◽  
Bin-Bin Gong ◽  
...  
Keyword(s):  
Laparoscopic Adrenalectomy ◽  
Operative Time ◽  
Haemodynamic Instability ◽  
Robot Assisted ◽  
Improvement Rate ◽  
Long Term Follow Up ◽  
Tumour Characteristics ◽  
Group 1

Abstract Background To evaluate the feasibility and safety of robot-assisted retroperitoneal laparoscopic adrenalectomy (RARLA) for large pheochromocytomas (PHEOs; size≥6 cm) compared with retroperitoneal laparoscopic adrenalectomy (RLA). Methods Fifty-one patients who underwent adrenalectomy for large PHEOs between March 2016 and January 2019 were enrolled and divided into two groups, including 32 RLA cases and 19 RARLA cases. We compared the perioperative efficacy and long-term follow-up results between the two groups. Results Preoperative data, including demographics, comorbidities and tumour characteristics, were similar between the groups. Intraoperatively, the RARLA group had a lower incidence of haemodynamic instability (26.3% vs. 56.2%, P = 0.038) and less intraoperative blood loss (100 ml vs. Two hundred milliliter, P = 0.042) than the RLA group. The groups showed no significant differences in operative time or transfusion rates. Postoperatively, the time to diet resumption, time to ambulation, time to drainage removal and postoperative hospital stay were shorter in the RARLA group than in the RLA group (1 d vs. 2 d, P = 0.027; 1 d vs. 2 d, P = 0.034; 3 d vs. 5 d, P = 0.002; 5 d vs. 6 d, P = 0.02, respectively). The groups exhibited no significant differences in the duration of anaesthetic use, complications, or long-term follow-up results for the blood pressure (BP) improvement rate. Conclusions Compared with RLA, RARLA is a safe, feasible and even optimized procedure for large PHEOs.

OC.05.6: Long-Term Follow-Up of Patients with Branch-Duct IPMN of the Pancreas: Predictive Variables of Malignancy Development

2017 ◽  
Vol 49 ◽  
pp. e90
Author(s):  
P. Magnoni ◽  
M.C. Petrone ◽  
E. Dabizzi ◽  
S.G.G. Testoni ◽  
A. Mariani ◽  
...  
Keyword(s):  
Branch Duct ◽  
Predictive Variables ◽  
Long Term Follow Up

Long-term follow-up of serous ovarian tumors of low malignant potential

1992 ◽  
Vol 47 (2) ◽  
pp. 150-158 ◽  
Author(s):  
Jonathan F. Leake ◽  
John L. Currie ◽  
Neil B. Rosenshein ◽  
J.Donald Woodruff
Keyword(s):  
Malignant Potential ◽  
Ovarian Tumors ◽  
Low Malignant Potential ◽  
Long Term Follow Up

scholarly journals Treatment of terrible triad injuries at a mean follow-up of nine years

2018 ◽  
Vol 11 (6) ◽  
pp. 450-458 ◽  
Author(s):  
Ezequiel E Zaidenberg ◽  
Mariano O Abrego ◽  
Agustin G Donndorff ◽  
Jorge G Boretto ◽  
Pablo De Carli ◽  
...  
Keyword(s):  
Terrible Triad ◽  
Performance Score ◽  
Level Of Evidence ◽  
Mayo Elbow Performance Score ◽  
Flexion Extension ◽  
Long Term Follow Up ◽  
Radiological Changes ◽  
One Year

Background To evaluate the sustainability of the early clinical and radiological outcomes of terrible triad injuries at long-term follow-up. Methods Twelve consecutive patients who underwent fixation of terrible triad injuries with minimum of seven years of follow-up. Functional and radiological outcomes at one year and final follow-up were compared. We assessed Mayo Elbow Performance Score, Quick-Disability of the Arm Shoulder and Hand, and modified-American Shoulder and Elbow Surgeons Scores. Radiological evaluation included Broberg and Morrey classification and Hastings classification for heterotopic ossification. Results The mean age of patients was 55 years, with a median follow-up of 9.3 years. At final evaluation, mean flexion, extension, supination, and pronation were 145°, 6°, 82°, and 80°, respectively; mean Mayo Elbow Performance Score, modified-American Shoulder and Elbow Surgeons Scores, and Quick-Disability of the Arm Shoulder and Hand scores were, respectively, 97, 92, and 4.9 points. There was no statistical difference between early and final follow-up range of motion, Mayo Elbow Performance Score, and Quick-Disability of the Arm Shoulder and Hand. However, radiological changes were observed in 66% of the patients at final follow-up. Two patients underwent reoperation, with final satisfactory results. Conclusion Our results suggested that using a standardized protocol, satisfactory clinical outcomes at early follow-up could be maintained over time. However, early complications and osteoarthritic changes at long-term follow-up can be expected. Level of evidence Therapeutic IV Cases series.

Long-term survival and toxicity in patients with progressive advanced neuroendocrine tumors treated with lutetium peptide radiolabelled radiotherapy: A Western Australian long-term follow-up study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16202-e16202
Author(s):  
Kim Robyn Kennedy ◽  
Phillip Claringbold ◽  
William Macdonald ◽  
Glenn Boardman ◽  
David Turner Ransom ◽  
...  
Keyword(s):  
Overall Survival ◽  
Neuroendocrine Tumours ◽  
Progression Free Survival ◽  
Somatostatin Analogue ◽  
Term Survival ◽  
Free Survival ◽  
Follow Up Study ◽  
Long Term Follow Up

e16202 Background: There are limited treatment options for advanced neuroendocrine tumours, and radiolabelled somatostatin analogues have shown favourable safety and efficacy over other existing treatments. Lutetium Octreotate has been shown to be the somatostatin analogue of choice in Peptide Radiolabelled Radiotherapy (PRRT) for advanced neuroendocrine tumours (NETs). Methods: We conducted a retrospective review of the long term safety and survival outcomes of 104 patients prospectively treated on the CLEMENT1, CLEMENT2, NETTLE, and NETT VALuE trials where patients with advanced progressive NETs were treated with Lutetium Octreotate PRRT in Perth, Western Australia. With a median follow-up time of 68 months, this is the longest follow-up study of advanced NETs treated with Lutetium PRRT in the literature to date. Results: Results showed comparable periods of disease stability as other studies, with median progression free survival of 43 months, and superior survival to other series, with a median survival of 71 months. There were patients who had very durable responses, with five year overall survival 61.5%, five year progression free survival 30.1%, 10 year overall survival 30.1%, and 10 year progression free survival of 29.3%, demonstrating Lu 177 can provide a very long duration of response in some patients. PRRT treatment was well tolerated with 1.9% of patients suffering long term renal impairment, and 1% with long term mild thrombocytopenia attributed to PRRT. Importantly, there was a higher rate of MDS and leukaemia in our series (6.7%), which is likely attributed to the longer period of follow-up with all except one case occurring 48 months after PRRT treatment, which is later than the median follow up in most other studies. Conclusions: Overall, this study showed that Lutetium PRRT remains an efficacious and well tolerated treatment in long term follow-up. For clinicians deciding on the timing of PRRT for individual patients the 6.7% long term risk of MDS/leukaemia needs to be balanced against the 29.3% PFS at 10 years. Clinical trial information: ACTRN12610000440022.

Long-Term follow-up of Patients with Branch-Duct IPMN of the Pancreas: Predictive Variables of Malignancy Development

2017 ◽  
Vol 152 (5) ◽  
pp. S670-S671
Author(s):  
Pietro Magnoni ◽  
Maria Petrone ◽  
Ilaria Pergolini ◽  
Emanuele Dabizzi ◽  
Mariaemilia Traini ◽  
...  
Keyword(s):  
Branch Duct ◽  
Predictive Variables ◽  
Long Term Follow Up

Bronchial Carcinoid Tumours in Children — A Review

2011 ◽  
Vol 07 (03) ◽  
pp. 196 ◽  
Author(s):  
Giovanna Rizzardi ◽  
Luca Bertolaccini ◽  
Alberto Terzi ◽  
◽  
◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Primary Lung Cancer ◽  
Radical Resection ◽  
Carcinoid Tumours ◽  
Long Term Follow Up ◽  
Bronchoplastic Procedures ◽  
Well Differentiated ◽  
Treatment Surgery

Bronchial carcinoids (BCs) are rare, well-differentiated malignant neuroendocrine tumours that account for 2–5 % of all lung neoplasms in adults. In paediatric patients, carcinoids represent the most frequent primary lung cancer. Although BCs in childhood often have an endobronchial location causing airway obstruction, they are frequently misdiagnosed as benign conditions, resulting in a delay in definitive diagnosis and treatment. Surgery represents the treatment of choice for BCs, and lung-sparing resections (sleeve or bronchoplastic procedures) are recommended in central carcinoid tumours; pneumonectomy should be avoided, particularly in childhood. If promptly diagnosed and radically treated, BCs in children have an excellent prognosis. Relapses can occur many years after a radical resection, highlighting the necessity for long-term follow-up.

Sign in / Sign up

Export Citation Format

Share Document